[PDF][PDF] Assessing the safety of stem cell therapeutics

…, NA Hanley, L Kelly, NR Kitteringham, J Kurth… - Cell stem cell, 2011 - cell.com
Unprecedented developments in stem cell research herald a new era of hope and expectation
for novel therapies. However, they also present a major challenge for regulators since …

First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant …

J Kurth, BJ Krause, SM Schwarzenböck… - European journal of …, 2020 - Springer
Purpose Besides PSMA, prostate cancer cells also express gastrin-releasing peptide receptor
(GRPr) which is therefore a promising target for theranostic approaches. The high affinity …

[HTML][HTML] The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment—beyond classical regression

SJ Teipel, J Kurth, B Krause, MJ Grothe… - NeuroImage: Clinical, 2015 - Elsevier
Selecting a set of relevant markers to predict conversion from mild cognitive impairment (MCI)
to Alzheimer's disease (AD) has become a challenging task given the wealth of regional …

Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survival

…, HS Willenberg, BJ Krause, J Kurth - Nuclear medicine …, 2018 - journals.lww.com
Objectives Peptide receptor radionuclide therapy (PRRT) with lutetium-177 (177 Lu)-DOTATATE
is regarded as a safe treatment option with promising results for patients with …

[HTML][HTML] Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre

…, A Santos, J Gear, PO Kiratli, J Kurth… - European Journal of …, 2022 - Springer
The theranostics concept using the same target for both imaging and therapy dates back to
the middle of the last century, when radioactive iodine was first used to treat thyroid diseases. …

Siponimod ameliorates metabolic oligodendrocyte injury via the sphingosine-1 phosphate receptor 5

…, L Frintrop, E Santrau, J Kurth… - Proceedings of the …, 2022 - National Acad Sciences
Multiple sclerosis (MS), an autoimmune-driven, inflammatory demyelinating disease of the
central nervous system (CNS), causes irreversible accumulation of neurological deficits to a …

Iterative learning control of a pneumatically actuated lung tumour mimic model for an improvement of PET/CT-imaging

A Wache, H Aschemann, BJ Krause, J Kurth - Mechatronics, 2022 - Elsevier
In this paper, a model-based tracking control is proposed for a mechanism dedicated to
accurately reproduce the breathing-induced motion of a human lung tumour. In former work, a 3-…

Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced …

…, M Eiber, G Kundt, M Retz, M Sakretz, J Kurth… - European journal of …, 2016 - Springer
Purpose The aim of this study was to prospectively evaluate the value of [ 11 C] Choline PET/CT
in monitoring early and late response to a standardized first-line docetaxel …

Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study.

…, L Blumenstein, P Klein, JR Basque, J Kurth - 2022 - ascopubs.org
97 Background: The phase 3 VISION trial (NCT03511664) evaluated the efficacy and safety
of the radioligand [ 177 Lu]Lu-PSMA-617 ( 177 Lu-PSMA-617) in patients with metastatic …

[HTML][HTML] Translational assessment of a DATA-functionalized FAP inhibitor with facile 68Ga-labeling at room temperature

A Escudero-Castellanos, J Kurth, S Imlimthan… - European journal of …, 2023 - Springer
Purpose The present study aims at evaluating the preclinical and the clinical performance of
[ 68 Ga]Ga-DATA 5m. SA.FAPi, which has the advantage to be labeled with gallium-68 at …